Newman, MD, during a press conference held March 29 in advance of the 2022 annual meeting of the American Academy of Neurology.ĭr. But for people whose vision is devastated by this disease, it certainly is a first step,” said Nancy J. “This is not hitting it out of the ballpark.
The results in the treated eye were encouraging, though modest. The study protocol called for injection of the therapy into one eye and a placebo into the other, using the patient as his or own placebo control. Once synthesized, a mitochondria-targeting sequence facilitates transport of the protein to the mitochondria. Researchers believe that the injected viral vector gets taken up retinal ganglion cells, where the mutated gene interferes with vision. The condition often starts with blindness in one eye, accompanied or followed shortly by blindness in the second eye. LHON is a rare, maternally inherited mitochondrial mutation that can cause blindness, most commonly in young men, though it does not happen in all individuals with the mutation. The therapy, delivered by intravitreal injection, uses an adeno-associated virus vector to deliver a corrected copy of the mutated ND4 mitochondrial gene.
MODEST EYES TRIAL
North American sales will double to 100,000 units in 2018, he predicts.SEATTLE – The latest data from a phase 3 clinical trial shows that gene therapy can counter visual degeneration associated with Leber hereditary optic neuropathy (LHON). Europe is expected to remain flat at about 700,000 vehicles, while Latin America creeps up to 800,000 units from 700,000.Īsia will show the greatest growth, rising to 300,000 deliveries from 70,000, Francois says. The compact CUV bows in 2017 and a new Panda arrives in 2018.įiat’s global goal is to increase sales to 1.9 million units in 2018, from 1.5 million in 2013.
MODEST EYES PLUS
In 2016 a compact hatchback and station wagon, plus a B-segment car, arrive. In Europe, Fiat will launch a new compact sedan in 2015, along with a specialty vehicle. The Punto and Grand Siena arrive in 2017 and a compact CUV bows in 2018. A D-sedan bows in 2016, along with a new Avventura. In Asia, Fiat gets the updated Ottimo, Punto and Avventura this year and adds an Ottimo CUV in 2015. A revamped Palio debuts in 2017 and a new Siena hits the market in 2018. In Latin America, where Fiat’s No.1 goal is to remain the sales leader in Brazil, there will be a new Uno FL this year, a new A-segment and compact-pickup entry next year and a new Punto, B-sized CUV and Grand Siena in 2016. Also on tap is an undefined “specialty” model Olivier says will be “in the heart of the market.” In North America, new models will be limited to the 500X, a CUV-type derivative of the 500 that is due in Europe this year but won’t make it to the U.S. Even on the value side, the brand’s cars will be positioned on the upper end of the price spectrum, he says.īecause Fiat focuses its lineup differently depending on market, its future product lineup varies from region to region. With vehicles focused on the two ends of the volume-model spectrum, Fiat will ignore the more cutthroat and unprofitable middle territory, Francois says. More value-priced vehicles will be stocked for immediate delivery, while aspirational models will lean toward build-to-order, Fiat-brand head Olivier Francois says here today. That duality even will transform Fiat dealerships and delivery methods in Europe, where showrooms will be divided in two to appeal to the separate sets of shoppers. AUBURN HILLS, MI – Fiat Chrysler Automobiles’ Fiat brand is aiming for a split personality with its product lineup, appealing to value-conscious buyers with some models and customers looking for more aspirational buys with another set of vehicles.
0 kommentar(er)
